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Abstract
Introduction: We recently presented a prediction score providing decision support with the often-challenging early
differential diagnosis of acute lung injury (ALI) vs cardiogenic pulmonary edema (CPE). To facilitate clinical adoption,
our objective was to prospectively validate its performance in an independent cohort.
Methods: Over 9 months, adult patients consecutively admitted to any intensive care unit of a tertiary-care center
developing acute pulmonary edema were identified in real-time using validated electronic surveillance. For eligible
patients, predictors were abstracted from medical records within 48 hours of the alert. Post-hoc expert review
blinded to the prediction score established gold standard diagnosis.
Results: Of 1,516 patients identified by electronic surveillance, data were abstracted for 249 patients (93% within
48 hours of disease onset), of which expert review (kappa 0.93) classified 72 as ALI, 73 as CPE and excluded 104 as
? other? . With an area under the curve (AUC) of 0.81 (95% confidence interval =0.73 to 0.88) the prediction score
showed similar discrimination as in prior cohorts (development AUC=0.81, P=0.91; retrospective validation AUC=0.80,
P=0.92). Hosmer-Lemeshow test was significant (P=0.01), but across eight previously defined score ranges probabilities
of ALI vs CPE were the same as in the development cohort (P=0.60). Results were the same when comparing acute
respiratory distress syndrome (ARDS, Berlin definition) vs CPE.
Conclusion: The clinical prediction score reliably differentiates ARDS/ALI vs CPE. Pooled results provide precise estimates
of the score?s performance which can be used to screen patient populations or to assess the probability of ALI/ARDS vs
CPE in specific patients. The score may thus facilitate early inclusion into research studies and expedite prompt treatment.
Background
With an estimated 190,600 new cases each year resulting
in 74,500 deaths and 3.6 million hospital days, acute
respiratory distress syndrome (ARDS [1], formerly known
as acute lung injury [ALI] [2]) poses a major health
burden on US society [3]. In the early stages ARDS can be
difficult to differentiate from cardiogenic pulmonary
edema (CPE) [4,5], which may delay initiation of critical
treatment measures (for example, lung-protective ventila-
tion, prone positioning, neuromuscular blockade) [6-10],
lead to unnecessary testing and preclude timely enrollment
into research studies [11-13].
In both practice and research, the diagnosis of ARDS
primarily rests on clinical judgment [4,14,15], which is
limited by its subjectivity and substantial inter-rater
variability. Therefore, we recently presented a prediction
score providing objective decision support for early
differential diagnosis of ARDS versus CPE based on
routinely available clinical data (free download of calculator
[16]) [17]. To facilitate clinical adoption of this prediction
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formance in an independent cohort of consecutive patients.
Materials and methods
During a 9-month period (March 2010 through January
2011) all adult patients admitted to any ICU at a tertiary
care center in Rochester, MN, USA, were screened for
new onset of acute pulmonary edema (defined as arterial
partial pressure of oxygen (PaO2)/inspired oxygen fraction
(FiO2) ratio <300 for arterial blood gas, and pulmonary
edema or bilateral infiltrates on chest radiograph as read
by radiologists, both within 24 h) using a previously
validated electronic surveillance system [7]. After being
alerted about these patients via email and the paging
system in real time, research staff reviewed the electronic
medical records (EMR) for potential eligibility within
48 h. Patients were excluded if they had been enrolled
in the previously reported development cohort (DC)
or retrospective validation cohort (RVC) [17], or if research
staff could not review their medical records within 48 h of
being alerted. The other exclusion criteria at this stage
were: no research authorization, second or later episodes of
acute pulmonary edema after enrollment, chest radiograph
findings clearly inconsistent with ALI (for example, lower
zone opacities only, chronic bilateral opacities; as empha-
sized in the Berlin definition of ARDS [1]), substantial
missing data, mechanical ventilation prior to (>6 hours)
development of acute pulmonary edema [17].
If patients were found potentially eligible, research staff
(AA and CS) directly abstracted most of the data neces-
sary for calculation of the prediction score from the EMR
into a predesigned access? form (some data at low risk of
differential measurement bias such as age were retrieved
retrospectively from a validated ICU database; details in
Additional file 1) [7].
Post-hoc expert review served as the gold standard:
after patients  discharge or death a board-certified
critical care physician (SP) and a clinical critical care
fellow (MA) - blinded to each other as well as to the
details and results of the prediction score - reviewed
all included patients after discharge or death, taking
into account all available information in the EMR including
the course of illness and response to therapeutic
intervention using the following definitions (with dis-
agreements resolved via super-review by an experienced
investigator [RK]) [17]: ALI was defined according to the
American-European Consensus Conference (AECC) state-
ment as acute (<24 h) hypoxemia (PaO2/FiO2 ratio <300)
with bilateral lung infiltrates consistent with pulmon-
ary edema on frontal chest radiograph without any
evidence of left atrial hypertension [2]. Left atrial
hypertension was excluded by echocardiographic findings
(E/E  <15), brain natriuretic peptide (BNP) levels
(BNP <250 pg/mL in the absence of renal failure), and
venous filling pressures (pulmonary wedge pressure ≤18
or central venous pressure ≤12 mmHg in the absence of
pulmonary hypertension).
CPE was defined by a combination of clinical signs
(jugular venous distension, systolic hypertension); radio-
graphic (cardiothoracic ratio >0.53 and vascular pedicle
width >0.65 mm), electrocardiogram (new ST-segment
and T-wave changes), laboratory (elevated troponin
T level >0.1 ng/mL), and hemodynamic findings
(pulmonary wedge pressure >18 mmHg, central venous
pressure >12 mmHg, decreased ejection fraction <45%,
E/E  >15, presence of severe left-sided valvular heart
disease (aortic or mitral stenosis or regurgitation)); and a
brisk response (hours) to appropriate therapy (preload/
afterload reduction, treatment of ischemia or inotropic
agents). Patients meeting both criteria were classified as
ALI+CPE; those meeting neither definition where classi-
fied as other and excluded from the main analysis.
During the study the Berlin definition for acute respira-
tory distress syndrome (ARDS) [1] was published replacing
the AECC definition for ALI [2]. We tried to account for
this by performing sensitivity analysis, in which ALI patients
w i t hap o s i t i v ee n d - e x p i r a t o r yp r e s s u r e( P E E P )m e a s u r e -
ment ≥5c m H 2O within 12 h of acute pulmonary edema
were classified as having ARDS (Berlin definition) [1].
The Mayo Clinic Institutional Review Board (IRB)
approved the use of medical records for research and
waived the requirement for written informed consent
as doing so would not have been feasible, and the risk
from this study for patients was minimal (IRB number
10-000348). Only patients who gave permission to use
their medical record for research (research authorization)
were included in this study.
Statistical analysis
Agreement between post-hoc expert reviewers was
evaluated by the kappa statistic. Patients with both
ALI and CPE were treated as ALI cases in all analyses
unless stated otherwise. Data were summarized as
median (IQR) or percent (number) for each group
(ALI versus CPE). Univariable analyses were carried out
using the Wilcoxon rank-sum test and the chi-squared or
Fisher exact test as appropriate. For multivariable analyses
a single imputation method was used (this value was
assumed for variables including 0 in the normal reference
range, otherwise, the overall median was chosen) [17].
Discrimination of the prediction score as judged by
the area under the receiver operating characteristic curve
(AUC) was formally compared with the results from the
two previous cohorts [17] (prospective validation cohort
(PVC) versus development cohort (DC) and retrospective
validation cohort (RVC)) using the chi-squared test. A
priori we decided to assess calibration using: 1) the
Hosmer-Lemeshow (HL) test, and 2) the chi-squared test
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numbers of ALI cases across eight score categories, which
had been previously defined during score development
[17] with:
NALI‐expected;PVC;i   Ntotal;PVC;i   ProbabilityALI;DC;i
for each score category i.
In sensitivity analyses the AUC was estimated: 1)
excluding patients with both conditions (ALI +CPE),
2) comparing ARDS (Berlin definition) [1] against CPE, 3)
using bootstrap analysis with 10,000 samples to assess the
robustness of results, and 4) comparing ALI versus
CPE+other and CPE versus ALI +other patients.
In post-hoc analysis we tried to identify predictors of
other versus ALI or CPE. We further compared the ob-
served versus expected number of ALI cases across the
eight pre-defined score categories in the (previously
published) retrospective validation cohort [17], and
driven by the results assessed in logistic regression
models if referral patient status (as a proxy for ALI versus
CPE prevalence) is an independent predictor of ALI versus
CPE. Lastly, post-hoc meta-analysis was performed in
which individual patient data from the current and previous
cohorts were combined to obtain pooled estimates for the
AUC (DC +RVC+PVC), the sensitivity/specificity at differ-
ent cutoff points (DC+RVC +PVC), and the probability of
ALI versus CPE for each of the eight pre-defined score
ranges (DC +PVC). Analyses were performed in JMP 9.0.3
and SAS 9.3 (SAS Institute Inc., Cary, NC, USA) using
two-sided P-values <0.05 to judge statistical significance.
Results and discussion
Of 1,516 patients identified by electronic surveillance,
data were abstracted from the EMR for 249 patients
(Figure 1). Agreement between post-hoc expert reviewers
was excellent (kappa=0.93). A total of 104 patients
(42%) were classified as   other  , as they did not meet
the criteria for ALI or CPE (general characteristics in
Additional file 2: Table S1), thus the final prospective
validation cohort (PVC) consisted of 145 patients (64
ALI, 8 ALI+CPE, 73 CPE). For 50% of these patients
predictor data were abstracted from the EMR within
12 h of onset of acute pulmonary edema (93% within
48 h). Patients with ALI were significantly younger,
more likely to require invasive mechanical ventilation
and had higher hospital mortality than CPE patients,
with 81% meeting ARDS criteria based on the Berlin
definition within 12 h of disease onset (Table 1).
Based on the AUC, the prediction score discriminated
equally well between ALI and CPE as in the two previous
cohorts (AUCPVC=0.81, 95% CI=0.73 to 0.88 compared
to AUCDC=0.81, P=0.85 and AUCRVC=0. 80 , P=0. 97 ;
Figure 2). In sensitivity analyses the AUC did not
change when (1) excluding patients with both ALI +CPE
(AUC =0.82, 95% CI=0.75 to 0.89; n =137), (2) predicting
ARDS (Berlin definition) [1] versus CPE (AUC=0.80, 95%
CI=0.73 to 0.88; n=131), or (3) bootstrapping the analysis
(AUC=0.81, 95% CI =73 to 0.88), but was substan-
tially lower when comparing ALI versus CPE+Other
(AUC =0.73, 95% CI=0.66 to 0.79; sensitivity/specificity in
Additional file 3: Table S2) or CPE versus ALI +Other
(AUC =0.71, 95% CI=0.64 to 0.78; sensitivity/specificity in
Additional file 3: Table S2). In post-hoc analysis the only
significant predictor of the category, other, compared to
ALI or CPE patients was the SpO2/FiO2-ratio at six h after
onset of respiratory failure (odds ratio (OR) =0.37, 95%
CI=0.22 to 0.64; P <0.001; see Additional file 4: Table S3).
Based on the HL test the score was not well-calibrated
when modeled as a linear or quadratic function of the log-
odds of ALI (P=0.0 1andP= 0.047), but clinically the dif-
ferences between observed and expected cases across dec-
iles of predicted probabilities were small (Additional file 5).
Also, when compared across the eight pre-defined score
ranges the number of observed versus expected ALI cases
did not differ in the prospective validation cohort (Figure 3;
P= 0.49).
In post-hoc analysis, we found significantly more ALI
cases than expected across the eight score ranges in the
retrospective validation cohort (P= 0.004). We hypothesized
that those results may be explained by higher prevalence of
ALI versus CPE in referral patients, but referral status
Figure 1 Study flowchart. ALI, acute lung injury; CPE, cardiogenic
pulmonary edema.
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in the prospective validation cohort (P =0.14; details
in Additional file 6). Based on pooled data the AUC
was 0.81 (95% CI=0.78 to 0.84). Pooled estimates for
(1) sensitivity/specificity at various cutoffs are shown
in Additional file 7: Table S4, and (2) the probabilities
of ALI versus CPE (and vice versa) across the eight
score ranges are presented in Figure 4.
This prospective validation provides further evidence
that the prediction score differentiates well between ARDS
and CPE patients. The score can be used in two different
ways: (1) to screen a patient population (for example, for
early enrollment of ARDS patients into a clinical trial)
by using a cutoff value: given the similar settings and
r e s u l t sw ed e c i d e dt op o o lt h ed a t af r o ma l lt h r e e
currently existing cohorts to obtain more precise esti-
mates for the sensitivity/specificity at different cutoffs
(Additional file 7: Table S4); (2) to estimate the probability
of ARDS versus CPE for a specific patient based on the
patient s score result. This probability could be derived
from a logistic regression function regressing the observed
outcomes against the prediction score, but based on
Table 1 General characteristics
Prospective validation cohort
n ALI/ALI+CPE (n=72) CPE (n=73) P-value
General Characteristics
Age, years 61 (49 to 69) 73 (63 to 79) <0.001
<45 years 13 (9) 7 (5) 0.25
Female sex 50 (36) 40 (29) 0.21
Body mass index 27 (23 to 35) 27 (24 to 32) 0.73
APACHE III score 53 (38 to 73) 52 (36 to 69) 0.70
Charlson score 2 (0 to 3) 2 (1 to 5) 0.07
Smoking 132 37 (25) 46 (30) 0.30
Referral patient 82 (59) 75 (55) 0.33
Admission ICU 0.04
medical 61 (44) 78 (57)
surgical 10 (7) 10 (7)
mixed 29 (21) 12 (9)
Non-invasive ventilation only 4 (3) 23 (17) 0.001
Invasive mechanical ventilation 92 (66) 67 (49) <0.001
ARDS (Berlin definition [1])* 81 (58) na na
Hospital mortality 47 (34) 15 (11) <0.001
ALI risk factors
Sepsis 57 (41) 23 (17) <0.001
Pancreatitis 0 (0) 1 (1) 0.32
Pneumonia 33 (24) 11 (8) 0.001
Aspiration 8 (6) 0 (0) 0.01
CPE risk factors
History of coronary artery disease 11 (8) 47 (34) <0.001
History of congestive heart failure 11 (8) 33 (24) 0.002
New ST-changes/left-bundle branch block 110 8 (4) 31 (19) 0.003
Other predictors
Alcohol abuse 135 19 (13) 6 (4) 0.02
Chemotherapy 144 21 (15) 6 (4) 0.006
SpO2/FiO2 ratio at 6 h after onset of acute pulmonary edema 141 181 (129 to 267) 240 (175 to 436) 0.002
<235 141 71 (48) 43 (31) 0.001
Data are presented as median (IQR) or percent (number); Total number was 145 unless noted otherwise. *ALI patients with positive end-exiratory pressure ≥5cmH2O
within 12 h of acute pulmonary edema (94% met this criterion within 48 h). ALI, acute lung injury; ARDS, acute respiratory distress syndrome; CPE, cardiogenic
pulmonary edema; APACHE, acute physiology and chronic health evaluation; FiO2: inspired oxygen fraction; SpO2, peripheral oxygen saturation; na, not applicable.
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approach (details in Additional file 5). Thus, instead we
suggest estimation of this probability as the observed
proportion of patients with ARDS in the corresponding
score range. However, either approach essentially provides
a positive predictive value, which depends on the preva-
lence of ARDS versus CPE (PARDS prior) in the underlying
cohort. Thus, the estimated proportions of ARDS across
the eight score ranges shown in Figure 4 are only based on
the combined data from the development and prospective
validation cohort (PARDS prior approximately =0.5 in both
cohorts), and should only be applied to patients from
populations with similar prevalence of ARDS versus
CPE. Estimates from the retrospective validation cohort
could be used to estimate the probability of ARDS versus
CPE in patients from populations with a PARDS prior
approximately=0.7 (see Additional file 6).
Other tests for differentiating ARDS versus CPE have
been proposed. For example low levels of BNP are indica-
tive of ARDS as opposed to CPE [18,19], but the high
prevalence of renal failure among critically ill patients
limits its usefulness [18,20]. The value of other more
investigational laboratory markers such as Clara Cell
protein 16 or Copeptin is less clear, and they likely suffer
from the same limitations as BNP [21,22].
Ultrasonography is used increasingly commonly in clinical
practice [23]. Its advantages are that it can be performed
quickly, has virtually no side effects, and may provide guid-
ance even in patients for whom no past medical history is
available (which would preclude calculation of the clinical
prediction score). However, sonographic visibility is often
limited in the ICU due to the presence of multiple devices,
chest trauma, surgical incisions or obesity. Furthermore its
diagnostic value is operator-skill dependent, and its applica-
tion requires substantial pre-training, the availability of ex-
pensive equipment and direct patient contact (prohibiting
its use in e-ICU (electronic intensive care unit) settings).
Additional tests that have been proposed to differenti-
ate ARDS versus CPE include the pulmonary vascular
permeability index [24] and the fluid-to-plasma protein
ratio [25], but these methods require the presence of an
invasive thermodilution device or direct sampling of
Figure 2 Overlying receiver operating characteristic curves.
Development cohort (DC; AUC =0.81, 95 CI =0.77 to 0.86), retrospective
validation cohort (RVC; AUC=0.80, 95% CI=0.72 to 0.88) and
prospective validation cohort (PVC; AUC=0.81, 95% CI=0.73 to 0.88).
Figure 3 Percent (and 95% CI) acute lung injury (ALI) cases observed (light gray bars) versus expected (dark gray bars) for each of the
eight previously published prediction score ranges. The number/percent of expected ALI cases is based on the observed percentages of ALI
cases across the eight score categories in the development cohort, which is used by the online calculator to translate a given patient?s score sum
into the predicted probability of ALI versus cardiogenic pulmonary edema (CPE) [17]. Based on the Chi-squared test with 7 degrees of freedom
there were no significant differences in observed versus expected number of ALI cases overall (P=0.49).
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to selected patients only.
Strengths of our study include the enrollment of
consecutive patients using a prospective study design:
95% of patients identified by electronic surveillance
were evaluated for eligibility and predictor data were
collected early after the onset of acute pulmonary edema,
thus, minimizing the risk of selection and measurement
bias, respectively. A further strength is that several sensi-
tivity analyses demonstrated robustness of results thus
providing further evidence for internal validity.
The main weakness is that generalizability of our
results may be limited because this and the previous
(development +retrospective validation) cohorts were
recruited at the same institution. Furthermore, use of the
score to predict an individual sr i s ko fA R D Sv e r s u sC P Ei s
restricted to settings with a similar underlying prevalence as
discussed above. Another limitation is that during the
course of this study the Berlin definition for ARDS [1] was
published replacing the previous ALI definition [2]. The
biggest difference is the newly introduced requirement of a
PEEP of ≥5c m H 2O [1]. While the time frame has not been
defined, as expected, the majority of included ALI patients
met this criterion within 12 h of onset of acute respiratory
failure (94% within 48 h), and while all main analyses com-
pared ALI versus CPE patients, the results did not change
when limiting ALI patients to this subset, suggesting that
the results apply equally to ARDS versus CPE patients.
Further, sample size of the validation cohort was
somewhat limited, but results did not change when
using a bootstrap procedure (simulating the sampling of
10,000 cohorts of the same size from the underlying
population) making it unlikely that random sampling
variability had a substantial effect on the results.
While we believe that clinically it is usually relatively
easy to distinguish patients with pulmonary edema (ALI
or CPE) from those with other etiologies mimicking
acute pulmonary edema at the onset illness (for example,
atelectases, acute chronic interstitial lung disease, diffuse
alveolar hemorrhage), in this study we deferred this
evaluation to the post-hoc review by design for two
reasons: 1) to minimize the potential for differential
measurement bias we tried to separate collection of
predictor data and outcome assessment as much as
possible, and thus, did not want the person who collected
the predictor data to evaluate the potential cause of the
patients  condition; 2) due to the lack of expert clinical
knowledge by the research personnel who abstracted the
predictor data we intentionally decided to be rather
over-inclusive at the stage of data abstraction to prevent
possible exclusion of ALI/CPE cases (which would have
reduced internal validity). This approach limits our results
in that the main analysis assumes that all patients
with etiologies other than ALI/CPE can be recognized
at initial presentation. The more this assumption fails
the more we overestimated the score st r u ep e r f o r m a n c e .
While the study design did not allow us to test this
assumption, the sensitivity analyses comparing ALI versus
CPE+other (and CPE versus ALI+other) indicates
that in the worst-case scenario (if it was impossible
initially to sort out any patients classified as other)
the prediction score would still perform moderately
well (Additional file 3: Table S2 shows the increased
trade-offs for a high sensitivity or specificity as compared
to the best-case scenario in Additional file 7: Table S4).
Another limitation is that ARDS and CPE may coexist
[1,26]. Because our focus was to identify patients with
any ARDS component we decided to include ALI +CPE
Figure 4 Pooled estimates for the probability (and 95% CI) of acute lung injury (ALI) versus cardiogenic pulmonary edema (CPE)
(gray bars) and CPE versus ALI (white bars) across eight previously published prediction score ranges (based on combined data from
the development and prospective validation cohort (n= 477). Overall prevalence of ALI versus CPE=48%.
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also concurring with previous practice [17,26]. The
number of patients with both conditions was small
(n = 8), thus, the results did not change when excluding
these patients in a sensitivity analysis and as expected
most of these patients had intermediate scores (data not
shown). In addition our study is limited by the lack of a
true gold standard for both ARDS and CPE and the fact
that oxygenation in some patients is impaired simply by
fluid overload without overt heart failure.
One promising future application of the prediction
score would be its integration into EMR infrastructure
to automate calculation. The results could be used in
various ways: for example to provide near real-time decision
support to (junior) physicians, to alert research staff, or for
quality assurance (for example, sending pager messages to
healthcare personnel if a patient at high risk of ARDS does
not receive low tidal volume ventilation) [27]. However, for
EMR integration one challenge will be to filter out patients
who have neither ARDS nor CPE automatically, as the
score s performance will otherwise be reduced (see
Discussion above). Future research should: 1) validate
the score in a different institutional setting (preferentially
using a multicenter design), 2) identify predictors of
ARDS/CPE versus other etiologies, 3) assess the feasibility
of integrating the prediction score into EMR infrastructure,
4) evaluate the value of combining the clinical prediction
score with findings from ultrasound examinations
(especially in patients with intermediate score results), and
5) assess the impact of early differential diagnosis on
clinical patient outcomes.
Conclusions
In this prospective validation the clinical prediction
score again demonstrated good differentiation between
ARDS and CPE. Pooled results provide precise estimates
of the score s performance which can be used to screen
patient populations or to assess the probability of ARDS
versus CPE in specific patients (if the underlying patient
populations are similar). The clinical prediction score
may thus facilitate early inclusion into research stud-
ies and expedite the initiation of critical treatment
measures.
Key messages
  The clinical prediction score differentiates ARDS
versus CPE reliably well across different patients
cohorts
  In populations with similar ARDS versus CPE
prevalence, the percentage of ARDS/CPE patients
across eight score ranges is similar and can be used
to predict an individual patient?s risk of ARDS versus
CPE (and vice versa)
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